Home Biotechnology Formycon AG
F

Formycon AG

Profile managed by Bizz Id
Germany

Description

Formycon AG is a German biosimilar developer covering technical-pharmaceutical development, clinical trials and regulatory dossiers. It has approved biosimilars of ranibizumab, ustekinumab and aflibercept, marketed by partners in Europe, the US and other markets, and is developing candidates including pembrolizumab and dupilumab.

Products

5 products
Aflibercept

FYB203. Eylea biosimilar. nAMD, DME, CNV, PDR, RVO. Partner brands: Ahzantive (Teva, Europe; Valorum Biologics, US and Canada), Baiama (Horus Pharma, Europe; NTC, Italy), Fovlya (MS Pharma, MENA). US launch planned Q4 2026.

Aprobado Comisión Europea; Aprobado FDA; Aprobado Reino Unido

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Aflibercept: see suppliers →

Dupilumab

FYB208. Dupixent biosimilar candidate (IL-4/IL-13). Atopic dermatitis, severe asthma, CRSwNP, COPD. Technical development (technical proof of similarity, Nov 2025); phase not stated.

Under development

Finished product (FDF)

Verified on 2026-10-21

Dupilumab: see suppliers →

Pembrolizumab

FYB206. Keytruda biosimilar candidate (PD-1 inhibitor). Clinical stage: PK equivalence study completed; FDA-agreed programme without Phase III. Partners: Zydus (US/Canada), MS Pharma (MENA), Lotus (APAC).

Under development

Finished product (FDF)

Verified on 2026-10-21

Pembrolizumab: see suppliers →

Ranibizumab

FYB201. Lucentis biosimilar. Severe retinal diseases (wet AMD, DME, CNV, PDR, RVO). Partner brands: Ranivisio (Teva, EU and Canada; Biomm, Brazil), Ongavia (Teva, UK), Cimerli (Sandoz, US, interchangeable), Nufymco (Zydus, US), Epruvy (Sandoz, Germany), Ranopto (Teva, Canada), Ravegza and Uptera (MS Pharma, MENA).

Aprobado Comisión Europea; Aprobado MHRA; Aprobado FDA; Aprobado Canadá; Aprobado Brasil; Aprobado MENA

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ranibizumab: see suppliers →

Ustekinumab

FYB202. Stelara biosimilar (ustekinumab-aauz in the US). Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis. Partner brands: Otulfi (Fresenius Kabi), Fymskina (Teva/ratiopharm, Germany), Sitovab (MS Pharma, MENA).

Aprobado Comisión Europea; Aprobado FDA; Aprobado MHRA; Aprobado Health Canada

Filing submitted

Finished product (FDF)

Verified on 2026-10-21

Ustekinumab: see suppliers →

Contact company

Register for free to see this company’s contact details and get in touch.

Register - Free